

APPROACH TO HAEMOLYSIS AND HAEMOGLOBINOPATHIES

BY:

**DR. FATMA AL-QAHTANI
CONSULTANT HAEMATOLOGIST
HEAD OF HAEMATOLOGY DIVISION
DEPARTMENT OF PATHOLOGY**

LEARNING OBJECTIVES

- To be able to define haemolysis and haemolytic anaemia
- To be able to classify haemolytic anaemias into congenital and acquired types, and to know the aetiological factors in each division
- To understand the difference between intravascular and extra-vascular haemolysis, and to recognise the laboratory features of each

cont'd...

- To appreciate that disorders of globin function such as sickle cell disease are subtypes of haemolytic anaemia
- To understand the role of autoantibodies in the production of haemolytic anaemias and to know the types of disease with which they are associated
- To understand some causes of non-immune acquired haemolytic anaemias

HAEMOLYSIS

- Premature destruction of RBCs.
- Hemolysis could be due to:
 - a. Defect in the RBCs (intra-corporcular) as in congenital hemolytic Anaemia.
 - b. Defect in the surrounding environment (extracorporcular) as in acquired Anaemia.

Classification Of Haemolytic Anaemias

Hereditary

Haemoglobin

Abnormal (Hb S, Hb C, unstable)

Thalassaemia

Membranopathy

Enzymopathy

Acquired

Allografts, especially marrow transplantation
drug associated

Red cell fragmentation syndrome

Arterial grafts, cardiac valves

Microangiopathic

Thrombotic thrombocytopenic purpura

Haemolytic uraemic syndrome

Meningococcal sepsis

Pre-eclampsia

Disseminated intravascular coagulation

March haemoglobinuria

Infections

Malaria, clostridia

Chemical and physical agents


Especially drugs, industrial/domestic substances,
burns

Secondary

Liver and renal disease

Paroxysmal nocturnal haemoglobinuria

Aetiological classification of haemolysis



A classification of haemolytic anaemia by aetiology. Abbreviations: G6PD, glucose-6-phosphate dehydrogenase; MAHA, microangiopathic haemolytic anaemia.

HAEMOLYTIC ANAEMIAS

Haemolysis

- describes the shortening of the lifespan of a mature red blood cell.
- increased red cell output from the marrow
- stimulated by erythropoietin
- will be sufficient to compensate for the increased red cell destruction
- more marked reductions in red cell lifespan - say to 5-10 days from the usual 120 days
- will result in *haemolytic anaemia*
- this compensatory increase in erythroid output requires an adequately functioning bone marrow and effective erythropoiesis
- a suboptimal marrow response is seen
- haemolysis will result in anaemia more readily

Clinical Features of Hemolysis

- **Pallor, lethargy**
- **Jaundice**
- **Splenomegaly**
- **Gall stones (Pigment – bilirubin)**
- **Dark urine (urobilinogen)**
- **Bone deformity (In some types of haemolytic anaemia)**
- **Leg ulcers (in some types of haemolytic anaemia).**

Laboratory Features of Hemolysis

1.) Features of increased red cell breakdown.
 - a. ↑ serum bilirubin is raised (unconjugated and bound to albumin).
 - b. ↑ urine urobilinogen.
 - c. ↑ faecal stercobilinogen.
 - d. Absent serum haptoglobins.
 - e. ↑ lactate dehydrogenase (LDH)

Laboratory Features of Hemolysis

2.) Features of increased red cells production.

- a. Reticulocytosis
- b. Bone marrow erythroid hyperplasia.

3.) Damaged red cells.


- a. Morphology (e.g. microspherocytes, elliptocytes, red cells fragmentation).
- b. Increased osmotic fragility, autohaemolysis etc).
- c. Shortened red cell survival (This can be shown by ^{51}Cr labeling with study of the sites of destruction.

Intravascular and extravascular haemolysis

- a. Intravascular haemolysis, the process of breakdown of red cells directly in the circulation.**
- b. Extravascular haemolysis excessive removal of red cells by cells of RE system in the spleen and liver.**


(a)

Extravascular





(b)

Intravascular



The main laboratory features of intravascular haemolysis are as follows:

- 1. Haemoglobinaemia and haemoglobinuria.**
- 2. Haemosiderinuria (Iron storage protein in the spun deposit of urine).**



Causes of intravascular haemolysis

- **Mismatched blood transfusion (usually ABO)**
- **G6PD deficiency with oxidant stress**
- **Red cell fragmentation syndromes**
- **Some autoimmune haemolytic anaemias**
- **Some drug-and infection-induced haemolytic anaemias**
- **Paroxysmal nocturnal haemoglobinuria**
- **March haemoglobinuria**
- **Unstable haemoglobin**

HAEMOLYTIC ANAEMIA

A . CONGENITAL

SICKLE CELL DISEASE & OTHER
HAEMOGLOBIN DISORDERS


THALASSAEMIAS

ENZYMOPATHIES


MEMBRANOPATHIES

B. ACQUIRED

SICKLE CELL ANAEMIA




THALASSAEMIA MAJOR



SICKLE BETA-THALASSAEMIA






Schematic diagram of the red cell membrane cytoskeleton.

SPHEROCYTOSIS




SPHEROCYTOYSIS


NEW BORN




STOMATOCYTOSIS



ACANTHOCYTOSIS





Abnormal Haemoglobins (Haemoglobinopathies)

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
VAL-HIS-LEU-THR-PRO-GLU-GLU-LYS-SER-ALA-VAL-THR-ALA-LEU-TRY

16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
GLY-LYS-VAL-ASN-VAL-ASP-GLU-VAL-GLY-GLY-GLU-ALA-LEU-GLY-ARG

31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
LEU-LEU-VAL-VAL-TYR-PRO-TRY-THR-GLN-ARG-PHE-PHE-GLU-SER-PHE

46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
GLY-ASP-LEU-SER-THR-PRO-ASP-ALA-VAL-MET-GLY-ASN-PRO-LYS-VAL

61 62 63 64 65 66 67 68 69 70 71 72 73 74 75
LYS-ALA-HIS-GLY-LYS-LYS-VAL-LEU-GLY-ALA-PHE-SER-ASP-GLY-LEU

76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
ALA-HIS-LEU-ASP-ASN-LEU-LYS-GLY-THR-PHE-ALA-THR-LEU-SER-GLU

91 92 93 94 95 96 97 98 99 100 101 102 103 104 105
LEU-HIS-CYS-ASP-LYS-LEU-HIS-VAL-ASP-PRO-GLU-ASN-PHE-ARG-LEU

106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
LEU-GLY-ASN-VAL-LEU-VAL-CYS-VAL-LEU-ALA-HIS-HIS-PHE-GLY-LYS

121 122 123 124 125 126 127 128 129 130 131 132 133 134 135
GLU-PHE-THR-PRO-PRO-VAL-GLN-ALA-ALA-TYR-GLN-LYS-VAL-VAL-ALA

136 137 138 139 140 141 142 143 144 145 146
GLY-VAL-ALA-ASN-ALA-LEU-ALA-HIS-LYS-TYR-HIS

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
VAL-LEU-SER-PRO-ALA-ASP-LYS-THR-ASN-VAL-LYS-ALA-ALA-TRY-GLY

16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
LYS-VAL-GLY-ALA-HIS-ALA-GLY-GLU-TYR-GLY-ALA-GLU-ALA-LEU-GLU

31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
ARG-MET-PHE-LEU-SER-PHE-PRO-THR-THR-LYS-THR-TYR-PHE-PRO-HIS

46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
PHE-ASP-LEU-SER-HIS-GLY-SER-ALA-GLN-VAL-LYS-GLY-HIS-GLY-LYS

61 62 63 64 65 66 67 68 69 70 71 72 73 74 75
LYS-VAL-ALA-ASP-ALA-LEU-THR-ASN-ALA-VAL-ALA-HIS-VAL-ASP-ASP

76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
MET-PRO-ASN-ALA-LEU-SER-ALA-LEU-SER-ASP-LEU-HIS-ALA-HIS-LYS

91 92 93 94 95 96 97 98 99 100 101 102 103 104 105
LEU-ARG-VAL-ASP-PRO-VAL-ASN-PHE-LYS-LEU-LEU-SER-HIS-CYS-LEU

106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
LEU-VAL-THR-LEU-ALA-ALA-HIS-LEU-PRO-ALA-GLU-PHE-THR-PRO-ALA

121 122 123 124 125 126 127 128 129 130 131 132 133 134 135
VAL-HIS-ALA-SER-LEU-ASP-LYS-PHE-LEU-ALA-SER-VAL-SER-THR-VAL

136 137 138 139 140 141
LEU-THR-SER-LYS-TYR-ARG

Some Known Haemoglobin Mutants

NAME	SUBSTITUTION
Hb. S	$\alpha_2 \beta_2$ 6 GLU \rightarrow VAL
Hb. C	$\alpha_2 \beta_2$ 6 GLU \rightarrow LYS
Hb. E	$\alpha_2 \beta_2$ 26 GLU \rightarrow LYS
Hb. O ARAB	$\alpha_2 \beta_2$ 121 GLU \rightarrow LYS
Hb. D PUNJAB	$\alpha_2 \beta_2$ 121 GLU \rightarrow GLN
Hb RIYADH	$\alpha_2 \beta_2$ 120 LYS \rightarrow ASN
Hb. HAMMERSMITH	$\alpha_2 \beta_2$ 42 PHE \rightarrow SER
Hb. N. BALTIMORE	$\alpha_2 \beta_2$ 95 LYS \rightarrow GLU
Hb. KORLE-BU	$\alpha_2 \beta_2$ 73 ASP \rightarrow ASN
Hb. K. WOOLWICH	$\alpha_2 \beta_2$ 132 LYS \rightarrow GLN
Hb. K. IBADAN	$\alpha_2 \beta_2$ 46 GLY \rightarrow GLU
Hb. KÖ LN	$\alpha_2 \beta_2$ 98 VAL \rightarrow MET
Hb. J. BALTIMORE	$\alpha_2 \beta_2$ 16 GLY \rightarrow ASP

Some Known Haemoglobin Mutants

NAME	SUBSTITUTION
Hb. G. PHILADELPHIA	$\alpha 2$ 68 ASN \rightarrow LYS $\beta 2$
Hb. ZAMBIA	$\alpha 2$ 60 LYS \rightarrow ASN $\beta 2$
Hb. G. CHINESE	$\alpha 2$ 30 GLU \rightarrow GLN $\beta 2$
Hb. HASHARON	$\alpha 2$ 47 ASP \rightarrow HIS $\beta 2$
Hb. J. TONGARIKI	$\alpha 2$ 115 ALA \rightarrow ASP $\beta 2$
Hb. J. OXFORD	$\alpha 2$ 15 GLY \rightarrow ASP $\beta 2$
Hb. NORFOLK	$\alpha 2$ 57 GLY \rightarrow ASP $\beta 2$

DNA Coding for the Amino-Acid in the sixth position in the β -chain


Normal

	5	6	7
Amino Acid	pro	glu	glu
DNA Base Composition	CCT	G A G	G A G

Sickle

DNA Base composition	CCT	G T G	G A G
Amino Acid	pro	val	glu
	5	6	7

HAEMOGLOBIN VARIANTS: GENE DISTRIBUTION



SICKLE CELL DISEASE

BY:

**DR. FATMA AL-QAHTANI
CONSULTANT HAEMATOLOGIST
HEAD OF HAEMATOLOGY DIVISION
DEPARTMENT OF PATHOLOGY**

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
VAL-LEU-SER-PRO-ALA-ASP-LYS-THR-ASN-VAL-LYS-ALA-ALA-TRY-GLY

16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
LYS-VAL-GLY-ALA-HIS-ALA-GLY-GLU-TYR-GLY-ALA-GLU-ALA-LEU-GLU

31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
ARG-MET-PHE-LEU-SER-PHE-PRO-THR-THR-LYS-THR-TYR-PHE-PRO-HIS

46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
PHE-ASP-LEU-SER-HIS-GLY-SER-ALA-GLN-VAL-LYS-GLY-HIS-GLY-LYS

61 62 63 64 65 66 67 68 69 70 71 72 73 74 75
LYS-VAL-ALA-ASP-ALA-LEU-THR-ASN-ALA-VAL-ALA-HIS-VAL-ASP-ASP

76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
MET-PRO-ASN-ALA-LEU-SER-ALA-LEU-SER-ASP-LEU-HIS-ALA-HIS-LYS

91 92 93 94 95 96 97 98 99 100 101 102 103 104 105
LEU-ARG-VAL-ASP-PRO-VAL-ASN-PHE-LYS-LEU-LEU-SER-HIS-CYS-LEU

106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
LEU-VAL-THR-LEU-ALA-ALA-HIS-LEU-PRO-ALA-GLU-PHE-THR-PRO-ALA

121 122 123 124 125 126 127 128 129 130 131 132 133 134 135
VAL-HIS-ALA-SER-LEU-ASP-LYS-PHE-LEU-ALA-SER-VAL-SER-THR-VAL

136 137 138 139 140 141
LEU-THR-SER-LYS-TYR-ARG

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
VAL-HIS-LEU-THR-PRO-GLU-GLU-LYS-SER-ALA-VAL-THR-ALA-LEU-TRY

16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
GLY-LYS-VAL-ASN-VAL-ASP-GLU-VAL-GLY-GLY-GLU-ALA-LEU-GLY-ARG

31 32 33 34 35 36 37 38 39 40 41 42 43 44 45
LEU-LEU-VAL-VAL-TYR-PRO-TRY-THR-GLN-ARG-PHE-PHE-GLU-SER-PHE

46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
GLY-ASP-LEU-SER-THR-PRO-ASP-ALA-VAL-MET-GLY-ASN-PRO-LYS-VAL

61 62 63 64 65 66 67 68 69 70 71 72 73 74 75
LYS-ALA-HIS-GLY-LYS-LYS-VAL-LEU-GLY-ALA-PHE-SER-ASP-GLY-LEU


76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
ALA-HIS-LEU-ASP-ASN-LEU-LYS-GLY-THR-PHE-ALA-THR-LEU-SER-GLU

91 92 93 94 95 96 97 98 99 100 101 102 103 104 105
LEU-HIS-CYS-ASP-LYS-LEU-HIS-VAL-ASP-PRO-GLU-ASN-PHE-ARG-LEU

106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
LEU-GLY-ASN-VAL-LEU-VAL-CYS-VAL-LEU-ALA-HIS-HIS-PHE-GLY-LYS

121 122 123 124 125 126 127 128 129 130 131 132 133 134 135
GLU-PHE-THR-PRO-PRO-VAL-GLN-ALA-ALA-TYR-GLN-LYS-VAL-VAL-ALA

136 137 138 139 140 141 142 143 144 145 146
GLY-VAL-ALA-ASN-ALA-LEU-ALA-HIS-LYS-TYR-HIS



DNA Coding for the Amino-Acid in the sixth position in the β -chain

Normal

	5	6	7
Amino Acid	pro	glu	glu
DNA Base Composition	CCT	G A G	G A G


Sickle

DNA Base composition	CCT	G T G	G A G
Amino Acid	pro	val	glu
	5	6	7

1910 **1st published report of sickle cell anaemia (Herrick)**

1949 **Pauling et al : chemical difference between HbA and HbS**

1956 **Ingram: Fingerprinting**
 β glu \longrightarrow val





AS



AS



AA



AS



AS



SS





AS



AC



AA



AC




AS



CS





?

?

S β -Thal



A β -Thal



AS



AA






AS



A β -Thal



AA



A β -Thal



AS



S β -Thal



SICKLE CELL DISEASE

THE SICKLE CELL TRAIT

HOMOZYGOUS SICKLE CELL DISEASE (SS)

Sickle cell anaemia

DOUBLY HETEROZYGOUS SICKLE CELL DISEASE

Sickle cell / haemoglobin C disease

Sickle cell / thalassaemia

PROPERTIES OF HbS

Solubility ↓

Conformational changes — “tactoid formation”

→ sickled cells

→ irreversibly sickled cells

↑ mechanical fragility → haemolysis

↑ viscosity → organ infarction

FACTORS AFFECTING SICKLING

Oxygen tension 50–60 mm Hg for SS
 20–30 mm Hg for AS

pH — inhibited at alkaline pH
 exacerbated by acidification

Concentration of Hb S

Presence of other haemoglobins

polymerisation : S > D > C > J = A > F


Sickling at low O₂ tension

**Increased
Viscosity**

PH


Low O₂ tension


Slow blood flow




FACTORS PRECIPITATING CRISES IN SICKLE CELL DISEASE


- ❖ INFECTIONS (especially malaria)
- ❖ PYREXIA
- ❖ EXPOSURE TO COLD
- ❖ DEHYDRATION
- ❖ PREGNANCY













HAEMOGLOBIN VARIANTS: GENE DISTRIBUTION





Frequency of sickle cell ($Hb S$) gene in different regions of Saudi Arabia

CRISES IN SICKLE CELL DISEASE

HYPERHAEMOLYTIC

AREGENERATIVE OR APLASTIC

SMALL VESSEL OCCLUSION

**CLINICAL MANIFESTATIONS
OF SICKLE CELL DISEASE**

**HAEMOLYTIC ANAEMIA
TISSUE INFARCTION**


Clinical Manifestations in Sickle Anaemia

- ❖ Pallor (Anaemia)
- ❖ Jaundice & Dark Urine
- ❖ Apathy & Anorexia
- ❖ Hand-Foot Syndrome (Young Children)
- ❖ Splenic sequestration (Young children) Hepatic Sequestration
- ❖ Bones and Joints Pain
- ❖ Abdominal Pain

Clinical Manifestations in Sickle Anaemia


- ❖ Recurrent Infections & Chest Symptoms (Acute Chest Syndrome)
- ❖ Hepato-Splenomegaly
 - ➔ (Early Childhood)
 - ➔ (Association with Thalassaemias)
- ❖ CNS Presentations
- ❖ Leg Ulceration
- ❖ Skeletal Deformity






















158














FIGURE 1. A CHICK OF THE SPECIES *SYNTHLIPSIA* LIES ON ITS BACK.














Laboratory Diagnosis of Sickle Cell Disease

- ❖ **CBC**
- ❖ **Blood Film**
- ❖ **Sickle Solubility Test**
- ❖ **Hb Electrophoresis**
- ❖ **Genetic Study**





SICKLE CELL SOLUBILITY TEST



Hb ELECTROPHORESIS

Indications for Blood Transfusion in Sickle Cell Anaemia

- ❖ Splenic sequestration
- ❖ Hepatic sequestration
- ❖ Aplastic crisis
- ❖ Overwhelming infections
- ❖ Elective or emergency surgical operation
- ❖ Severe painful crisis associated with severe haemolysis
- ❖ Pregnancy

Indications for exchange transfusion

- ❖ Strokes
- ❖ Pulmonary infarcts with infection
- ❖ Pregnancy (Severe persistent painful crisis)
- ❖ Priapism
- ❖ Preparation for major surgery



Thank you